表紙
市場調査レポート

OncoMed Pharmaceuticals, Inc.:製品パイプライン分析

OncoMed Pharmaceuticals, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 251699
出版日 ページ情報 英文 59 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
OncoMed Pharmaceuticals, Inc.:製品パイプライン分析 OncoMed Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日: 2015年08月31日 ページ情報: 英文 59 Pages
概要

OncoMed Pharmaceuticals, Inc. は、治療用モノクローナル抗体の開発をしているバイオテクノロジー企業です。同社はまた標的を定めた抗体や、他のタンパク質ベースの治療薬の開発も行っており、それらは癌の幹細胞を標的として変調させ、成長を抑制するよう設計されています。

当レポートでは、OncoMed Pharmaceuticals, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

OncoMed Pharmaceuticals, Inc.の基本情報

  • OncoMed Pharmaceuticals, Inc.の概要
  • 主要情報
  • 企業情報

OncoMed Pharmaceuticals, Inc.:R&Dの概要

  • 主な治療範囲

OncoMed Pharmaceuticals, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

OncoMed Pharmaceuticals, Inc.:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品 IND/CTA に申請された製品/併用療法モダリティ
    • 前臨床段階にある製品/併用療法モダリティ

OncoMed Pharmaceuticals, Inc.:薬剤プロファイル

  • demcizumab
  • tarextumab
  • ipafricept
  • OMP-52M51
  • vantictumab
  • OMP-305B83
  • Biologic for Cancer
  • Biologic to Inhibit Wnt Pathway for Cancer
  • Monoclonal Antibody to Inhibit Other Pathways for Cancer
  • OMP-131R10
  • Small Molecules for Oncology

OncoMed Pharmaceuticals, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

OncoMed Pharmaceuticals, Inc.:最近のパイプライン動向

OncoMed Pharmaceuticals, Inc.:休止中のプロジェクト

OncoMed Pharmaceuticals, Inc.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07416CDB

Summary

Global Markets Direct's, 'OncoMed Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the OncoMed Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of OncoMed Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of OncoMed Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of OncoMed Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the OncoMed Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate OncoMed Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of OncoMed Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the OncoMed Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of OncoMed Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of OncoMed Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of OncoMed Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • OncoMed Pharmaceuticals, Inc. Snapshot
    • OncoMed Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • OncoMed Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • OncoMed Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • OncoMed Pharmaceuticals, Inc. - Pipeline Products Glance
    • OncoMed Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • OncoMed Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • OncoMed Pharmaceuticals, Inc. - Drug Profiles
    • demcizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tarextumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • brontictuzumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ipafricept
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OMP-131R10
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OMP-305B83
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vantictumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biologic to Inhibit Wnt Pathway for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biologic to Target Hippo Pathway for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Other Pathways for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Agonize GITR for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • OncoMed Pharmaceuticals, Inc. - Pipeline Analysis
    • OncoMed Pharmaceuticals, Inc. - Pipeline Products by Target
    • OncoMed Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • OncoMed Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • OncoMed Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • OncoMed Pharmaceuticals, Inc. - Recent Pipeline Updates
  • OncoMed Pharmaceuticals, Inc. - Dormant Projects
  • OncoMed Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • OncoMed Pharmaceuticals, Inc., Key Information
  • OncoMed Pharmaceuticals, Inc., Key Facts
  • OncoMed Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • OncoMed Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • OncoMed Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • OncoMed Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2015
  • OncoMed Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • OncoMed Pharmaceuticals, Inc. - Phase II, 2015
  • OncoMed Pharmaceuticals, Inc. - Phase I, 2015
  • OncoMed Pharmaceuticals, Inc. - Preclinical, 2015
  • OncoMed Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • OncoMed Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • OncoMed Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • OncoMed Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • OncoMed Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • OncoMed Pharmaceuticals, Inc. - Dormant Developmental Projects,2015

List of Figures

  • OncoMed Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • OncoMed Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • OncoMed Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • OncoMed Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • OncoMed Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • OncoMed Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • OncoMed Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top